Hla-a3-restricted t cell receptors against braf with v600e mutation
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Servic
InventorsZhiya Yu, Catherine M. Ade, Matthew J. Sporn, James C. Yang, Ken-ichi Hanada
Life of this patent
Estimating the term…
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a human BRAFV600E amino acid sequence. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Claims27
An isolated or purified T cell receptor (TCR) having antigenic specificity for a human BRAFV600E amino acid sequence, wherein the TCR comprises the amino acid sequences of:
- (a) all of SEQ ID NO:
- 1-3;
- (b) all of SEQ ID NO:
- 4-6;
- (c) all of SEQ ID NO:
- 1-6;
- (d) all of SEQ ID NO:
- 11-13;
- (e) all of SEQ ID NO:
- 14-16;
- or
- (f) all of SEQ ID NO:
- 11-16.
2-4. (canceled)
(canceled)
(canceled)
(canceled)
An isolated or purified nucleic acid or a recombinant expression vector comprising the nucleic acid, wherein the nucleic acid comprises, from 5′ to 3′, a first nucleotide sequence and a second nucleotide sequence, wherein the first and second nucleotide sequence, respectively, encode the amino sequences of SEQ ID NOs:
- 7 and 8;
- 8 and 7;
- 9 and 10;
- 10 and 9;
- 17 and 18;
- 18 and 17;
- 19 and 20;
- 20 and 19;
- 27 and 28;
- 28 and 27;
- 29 and 30;
- 30 and 29;
- 31 and 32;
- 32 and 31;
- 33 and 34;
- 34 and 33;
- 35 and 36;
- 36 and 35;
- 37 and 38;
- 38 and 37;
- 39 and 40;
- 40 and 39;
- 41 and 42;
- or 42 and 41.
20-25. (canceled)
28-30. (canceled)
34-37. (canceled)
Dependencies are inferred from the claim text.